CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia

Published:2022-10 Issue:10 Volume:22 Page:774-779
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Lee Dasom,Jain Akriti G^ORCID,Deutsch Yehuda,Eatrides Jennifer,Chan Onyee,Padron Eric,Kuykendall Andrew^ORCID,Komrokji Rami,Lancet Jeffrey,Sallman David^ORCID,Talati Chetasi,Sweet Kendra^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study;Granfeldt Ostgard;J Clin Oncol,2015

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

3. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood,2009

4. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC)

5. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry;Hulegardh;Am J Hematol,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK;British Journal of Haematology;2024-07-08

2. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria;Blood Advances;2024-03-29

3. Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax;Pharmaceutics;2024-01-31

4. Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service;Clinical Lymphoma Myeloma and Leukemia;2023-10

5. Acute myeloid leukemia induction in the age of novel therapeutic agents;Canadian Hematology Today;2023-06-07